New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 5, 2013
05:47 EDTBIIBBiogen, Sobi announce publication of Phase 3 data for Alprolix
Biogen Idec and Swedish Orphan Biovitrum AB, or Sobi, announced the publication of detailed results from the pivotal Phase 3 study of Alprolix, the companies' investigational long-lasting recombinant factor IX Fc fusion protein candidate for haemophilia B. The study of Alprolix showed that people with severe haemophilia B safely and effectively prevented or reduced bleeding episodes with prophylactic infusions every one to two weeks. As the first long-lasting investigational therapy for haemophilia B to complete a Phase 3 study, Alprolix has the potential to be the first important advance in haemophilia B treatment in more than 16 years.
News For BIIB From The Last 14 Days
Check below for free stories on BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2014
16:45 EDTBIIBBiogen hemophilia drug Alprolix priced similar to older treatments, Reuters says
Subscribe for More Information
April 16, 2014
08:34 EDTBIIBPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
April 14, 2014
09:46 EDTBIIBBiogen hugs support at critical technical juncture, levels to watch
Subscribe for More Information
07:33 EDTBIIBBiogen to present Plegridy, Tecfidera data at AAN annual meeting
Subscribe for More Information
April 11, 2014
10:15 EDTBIIBBiogen heads for test of $280 area
The shares are heading lower after an early bounce attempt and are now just above the session low at $280.13. As noted yesterday, a break below $280 would confirm topping in the shares. Support below $280 is at $273.45. Resistance is at $285.
April 10, 2014
15:13 EDTBIIBBiogen tumbles, nearing important test of support
Subscribe for More Information
09:00 EDTBIIBBiogen May volatility elevated at 43 into Q1 and revenue outlook
Subscribe for More Information
07:31 EDTBIIBBiogen names Adam Koppel as SVP, Chief Strategy Officer
Subscribe for More Information
07:08 EDTBIIBBiogen announces positive top-line efficacy, safety results from Phase 3 trial
Biogen Idec and Swedish Orphan Biovitrum AB released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy of Eloctate, an investigational recombinant factor VIII Fc fusion protein product candidate, in children with severe haemophilia A. Eloctate was generally well-tolerated and no inhibitors were detected. Efficacy analyses showed twice-weekly prophylactic dosing with Eloctate maintained low bleeding rates in children.
April 8, 2014
07:22 EDTBIIBCaSA-ISPE to hold a conference
21st Annual Lilfe Sciences Technology Conference is being held in Raleigh, North Carolina on April 8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use